Natera, Inc. (NTRA) Earnings

Natera, Inc.

NTRA · NASDAQ-GS

Jun 2026upcoming

Next quarter

Consensus is -$0.47 EPS for Jun 2026 across 4 estimates, ranging -$0.59 to -$0.36.

NTRA Mar 2026

Reported May 7, 2026

Miss 5.66%

EPS estimate: -$0.53
EPS actual: -$0.56
Revenue estimate: —
Revenue actual: —
1-day move: -11.64%

Call highlights have not been generated for this quarter.

Symbol: NTRA
Type: Stock
Sector: Health Care
Industry: Medical Specialities
Country: North America
Exchange: NASDAQ-GS

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado.

Key Issues

Bullish view

The PMDA filing could broaden Signatera’s addressable market by enabling companion-diagnostic use in Japanese muscle-invasive bladder cancer.

Bearish view

The filing is only an application, not an approval, and the evidence gives no timetable, commercial terms, or expected revenue contribution.

Analyst Consensus

See all

Buy

14 analysts

$275

Current

—

Low

$295

Average

—

High

Average target implies +7.35% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Humana Inc.HUM · NYSE